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inTRODuCTiOn
Parkinson Disease (PD) is the second most common
neurodegenerative disease, after Alzheimer’s Disease
named by James Parkinson, who was the first one who
described it with medical terms in his report “An Essay
on the Shaking Palsy”.1 Although the disease was first
described in medical terminology in 1817 by Parkinson,
a description of the disease already existed in literature
from ancient times. Specifically in the Old Testament
there are at least two descriptions of “tremor” which
is the characteristic symptom of Parkinson’s disease.
James Parkinson himself confessed that he relied on
other previous studies of other scientists that described
tremor as a symptom of the disease. Among these sci-
entists that James Parkinson acknowledged, is one of
the greatest Greek doctors of ancient times, Galen
(129-126 AD) who first noticed and described various
types of terror that can appear as symptoms of the
disease.2
The main pathologoanatomical characteristic in
PD is the loss of dopaminergic neurons in substantia
nigra that result in discoloration of the solid portion
in substantia nigra. This is normal with aging but in
Parkinson’s disease it is greatly accelerated.3 The
physiological function of these neurons, which contain
melanin, is the production of dopamine, a main neu-
rotransmitter, which is necessary for the communi-
cation between nerve cells.3,4 Τhe degeneration of
these neurons greatly reduces the levels of dopamine
in the brain and this decrease affects mostly the control
of the movement in PD patients, who face a number
of motor symptoms5 like dyskinesia, resting tremor,
rigidity and instability. Besides kinetic problems, there
is also a number of non motor symptoms that PD pa-
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tients may experience. These include bowel dysfunc-
tion, hyposmia, depression and apathy, sleep disorders
and impaired mental functioning which can even lead
to dementia.5 The disease progression is gradual and
may take up to twenty years.6 For the evaluation of
the progress but also the severity of the disease, sci-
entists use various rating scales. Most frequently used
are Hoehn & Yahr scale and UPDRS(Unified Parkin-
son’s disease Rating Scale).5
Unfortunately, up to now there is no treatment
that can stop or even slow down the degeneration of
the brain neurons and as a result the disease evolves
slowly and gradually exhibits its symptomatology,
which is more pronounced as the neurodegeneration
progresses.1,7 The primary pathological feature, as
mentioned above, is the lack of dopamine, however
its exogenous administration is not effective due to
its low bioavailability since it cannot penetrate the
blood-brain barrier.8 Today there are several classes
of drugs that are administered to patients with Parkin-
son’s disease, either in combination or as monotherapy.
When medication is not effective then neurosurgery
is judged necessary.9
The main treatment that is given to PD patients
to alleviate mostly their motor symptoms is L-dopa,
a dopamine precursor. Normally, L-dopa is detected
in increased concentration in the tissues of the plant
Mucuna pruriens, which were used in ancient times
from the Indians for treating a neural disease, which
displays motor problems similar to those of Parkinson’s
disease.2 The first time that it was used to treat Parkin-
son’s disease was by Hornykiewicz in 1960, but the
results were not very encouraging. 7 years later, the
Greek, Georgios Kotzias, was the one who presented
the important results of the administration of synthetic
L-dopa to patients with Parkinson’s disease, helping
to establish L-dopa as a medication in Parkinsonian
patients.10
In the first years of its administration, L-dopa dra-
matically improves the day-to-day life of patients by
virtually eliminating the mobility problems they pre-
sent, but unfortunately its chronic use is connected
with additional motor symptoms like dyskinesia.11
For more than two decades and despite the devel-
opments and research in the field of Neuroscience,
the causes that lead to the development of Parkinson’s
disease remain unknown. It is argued that degeneration
of substantia neurons, which is the main pathological
feature in Parkinson’s disease, is due to genetic as
well as environmental factors. The environmental fac-
tors that affect the onset of the disease include rural
life, bacterial and viral infections, drinking water and
pesticides while coffee and smoking seem to act as
protective factors against neurodegeneration caused
by the disease. 12 As regards to genetic factors, a set
of genes have been associated with the onset of the
disease while several other genes are under investi-
gation (Olzweska McCarthy et al). Although only a
10-20% of PD cases have a family history, it is generally
accepted that PD has a genetic etiology.13 Recent s-
tudies found that Adenosine A2A receptor (Adora2A)
is highly expressed in the putamen-one of the basal
ganglia of the brain- of PD patients, as well as in pe-
ripheral blood cells.14 Furthermore, other studies
show that Adenosine A2A receptors are overexpressed
in the stratium of PD patients who exhibited Levodopa
Induced Dyskinesia (LID).15 That reveals a possible
connection between the gene that encodes Adora2A
and PD, as well as LID. The Adora2A gene encodes
the A2A adenosine receptor and is located in the long
arm of the 22th chromosome (22q11.23). Adora2A
gene includes a number of single nucleotide polymor-
phisms. Among them rs2298383 polymorphism (lo-
cated in the intron 1) attracts the interest, because of
its recent association with LID.11
The purpose of this study was to examine the role
of rs2298383 polymorphism of Adora2A gene in PD,
as well as the association between this particular poly-
morphism and LID, in a Greek cohort. 
METHODOlOGY
Our study group consisted of 127 individuals diagnosed
for sporadic PD [average age 63.39 ± 0.910 years
(range 38 – 83 years); average age at disease onset:
51.53 ± 0.950 years (range: 30 – 72 years)] according
to UK Parkinson’s Disease Society Brain Bank Clinical
Diagnostic Criteria (Hughes et al), in Papanikolaou
Hospital, Thessaloniki, Greece and 102 control indi-
viduals [average age: 74.42 ± 0.858 years (range: 61
– 94 years)]. Of the 127 patients with Parkinson’s dis-
ease studied, the 94 patients received medication as
L-dopa with average dosage the 629.39 ± 67.2 mg. 32
of them were free of dyskinesias, 24 showed dyskinesia
in 1-3 years after the initiation of medication with L-
dopa while 38 showed dyskinesia after 3 years from
the start of medication with L-dopa. In our associa-
tions, we count as positive, patients who experienced
dyskinesia in 1-3 years after the initiation of medication
with L-dopa. As negative we count patients that did
not experience dyskinesia at all and those who expe-
rienced dyskinesia after 3 years from the start of med-
ication with L-dopa. The presence of dyskinesia in
PD patients was evaluated with Unified Dyskinesia
Rating Scale. All the individuals of our control group
were neurologically examined and were found healthy
and had also a negative family history of neurological
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diseases. All PD and control individuals were ethnic
Greek residents of northern Greece, and gave in-
formed consent for this study. 
Genomic DNA was extracted in all subjects from
peripheral blood leukocytes according to standard
procedures. The rs2298383 genotypes were determined
using the PCR-RFLP method. Amplification of the
relative region encompassing this variant was accom-
plished using the following set of primers: forward
primer: 5’-CTG ACC GCG TGG AAT CCT AT-3’,
reverse primer: 5’-CCT CAC CAA GAG CAC TGG
AA-3’ 
PCR products were digested overnight, at 37 oC
with the BsoBI restriction enzyme (New England Bi-
olabs). Mutated homozygotes T/T were represented
by an undigested PCR 390 bp product. Mutated het-
erozygotes C/T were represented by the fragments
390+ 255 + 135 bp and the wild-type homozygotes
C/C were represented by the fragments 255+ 135 bp.
All fragments were were resolved on 2% agarose gel,
stained in ethidium bromide solution and visualized
with an ultraviolet light. Genotype and allele frequen-
cies were estimated by direct counting and were com-
pared between patients and controls by means of χ2
analysis. P < 0.05 was considered significant.
RESulTS
The genotype and allele distributions for the studied
rs2298383 polymorphism of Adora2A gene are shown
in tables 1 and 2. Statistically significant differences
were not found, either in genotype or allele frequencies
regarding the Adora2A rs2298393 polymorphism in
our total PD Greek cohort. When examining the sub-
group of PD patients with LID compared to PD pa-
tients without LID, no statistically significant differ-
ences were not found, either in genotype or in allele
frequencies, as well.
DiSCuSSiOn
Parkinson’s disease is a chronic disease, characterized
by degeneration of the brain’s nigral neurons. These
neurons have as a normal function the production of
a neurotransmitter, dopamine, which is necessary for
the transmission of messages between nerve cells.
Neurodegeneration therefore, leads to the appearance
of mainly motor problems in patients, which intensify
as the disease progresses.
Although the disease is inherited as a simple
Mendelian character in only 10-20% of all Parkinson’s
disease cases, a set of genes have been associated with
the onset of the disease while several other genes are
under investigation.16,17,18 The main drug that is given
to Parkinson’s disease patients is L-dopa, a dopamine
precursor that is primarily used to treat mostly the
kinetic symptoms of the disease. However, chronic
use of L-dopa from Parkinson’s patients results in ad-
ditional motor problems, namely dyskinesia. This
makes it even more difficult to treat the motor prob-
lems of the disease. An attempt to understand the
pathogenetic mechanisms that cause both the disease
and the dyskinesias that occur due to L-dopa, have
turned the interest of the researchers into the genes
involved in neurotransmission.19,20 Results of recent
investigations conducted by Casetta, Vincenzi et al.
show that A2A receptors of adenosine are elevated
in the shell, one of the basal ganglia of the brain, of
patients with Parkinson’s disease, indicating that there
may be correlation between the gene coding for these
receptors (Adora2A) and Parkinson’s disease.14 Ad-
ditional studies show elevated levels of adenosine
A2A receptors in the striatum of the brain of parkin-
sonian patients who have developed dyskinesia, re-
inforcing the previous view and therefore suggesting
that there might be some correlation between the
gene coding for these receptors (Adora2A) and the
disease.15 Apart from the studies that associate adeno-
sine A2A receptors with the disease, there are also
several studies, such as Cieślak, Komoszyśski et al.,
claiming that A2A receptor antagonists of adenosine
have neuroprotective activity.21 Tsuboi indirectly sup-
ports the same view, concluding that caffeine protects
against neurodegeneration by blocking A2A receptors
of adenosine thus demonstrating their important role
in neuroprotection.22 Cieślak, Komoszyśski et al. sug-
gest that adenosine A2A receptor antagonists when
given in combination with L-dopa may have a very
significant improvement in motor symptoms and also
may achieve neuroprotection that could delay or even
stop the progression of the disease.23 Thus, it is un-
derstood that A2A receptors of adenosine could be
new therapeutic targets for Parkinson’s disease. Morel-
li, Blantini et al. underline that, while many studies
have shown that adenosine A2A receptor antagonists
have positive effects on L-dopa dyskinesia, there are
not enough clinical tests to prove these findings.24 All
of this data suggest that the Adora2A gene should be
studied extensively in terms of its potential to be a
marker of predisposition for both Parkinson’s disease
and dyskinesias caused by L-dopa.
The Adora2A gene encodes the A2A receptor of
adenosine, a receptor that binds to G proteins and is
highly expressed in the striatum of the brain. There,
it competes with D2 dopaminergic receptors indirectly,
regulating the transmission of messages through the
neurons. It includes several polymorphisms of which
rs2298383 is of particular interest because of its positive
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correlation with the occurrence of L-dopa induced
dyskinesia in Parkinson’s disease patients, as studied
by Rieck, Schumacher-Shuh et al. in 2015. Since 2012
there was already a study by Greenbaum, Cohen et
al. which revealed the association of rs2298383 poly-
morphism of the Adora2A gene with L-dopa induced
dyskinesia.11 Generally, this polymorphism has been
associated with the appearance of many diseases. In
particular, Childs, Hohoff et. al in their study claim
that rs2298383 polymorphism of the Adora2A gene
causes increased anxiety due to caffeine consumption
(caffeine acts competitively against A2 adenosine re-
ceptors)25 while Freitag, Agelopoulos et al., after s-
tudying this polymorphism in relation to autism, found
that there was a correlation between them.26 Addi-
tionally, this polymorphism was associated with anxiety
disorder27 and schizophrenia.28 One study associated
Parkinson’s disease with two polymorphisms of the
Adora2A gene, namely rs2298383 and rs2298383.29
The data thus, suggest that there may be a correlation
between the Adora2A gene and Parkinson’s disease
or even between the rs2298383 gene polymorphism
with the occurrence of dyskinesia caused by L-dopa
medication in patients with Parkinson’s disease.
The present study aims to investigate the correla-
tion between the rs2298383 polymorphism of the Ado-
ra2A gene with Parkinson’s disease and the occurrence
of dyskinesia caused by L-dopa medication in Greek
patients with Parkinson’s disease. The results do not
reveal a statistically significant correlation of this poly-
morphism with either Parkinson’s disease or the oc-
currence of dyskinesia due to treatment with L-dopa.
It should be noted that there were some limitations
regarding the number of patients with Parkinson’s
disease studied. In particular, of the 127 patients with
Parkinson’s disease, only 24 had dyskinesia, so only
in these patients there was a possibility of studying
the distribution of alleles and genotypes of polymor-
phism. It is therefore necessary to conduct further
stu dies in the Greek population, including a larger
number of patients and other polymorphisms of the
Adora2A gene. 
COnCluSiOn
Adora2A has been acknowledged recently as a possible
candidate gene not only for Parkinson’s disease pre-
disposition, but also for the prediction of specific ad-
verse effects of L-dopa medication, such as dyskinesia.
In our PD Greek cohort, no statistically significant
differences were found, either in genotype or allele
frequencies regarding the Adora2A rs2298383 poly-
morphism. Moreover when examining the subgroup
of PD patients with LID compared to PD patients
without LID, no statistically significant differences
were found. However, additional studies including a
larger number of patients, and examining different
polymorphisms of Adora2A gene, will delineate the
role of Adora2A gene in the pathogenesis of PD, and
of Levodopa Induced Dyskinesia.
COnFliCTS OF inTEREST: nO
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Συσχέτιση μεταξύ του rs2298383 πολυμορφισμού του γονιδίου Adora2A και
της νόσου του Parkinson σε Έλληνες ασθενείς
Βασιλική Κάρπα, Καλλιρόη Καλινδέρη, Ανθή Χατζικυριακίδου, Χαράλαμπος 
Καρακάσης, Θεόδωρος Λιαλιάρης, Σεβαστή Μποσταντζοπούλου, Λιάνα Φιδάνη
Περίληψη: Σκοπός της συγκεκριμένης μελέτης ήταν η αναζήτηση συσχέτισης μεταξύ του rs2298383 πολυμορφισμού του
γονιδίου Adora2A με την νόσο του Parkinson, καθώς και με την εμφάνιση δυσκινησίας που προκαλείται από την φαρμακευτική
αγωγή με L-dopa σε Έλληνες ασθενείς με νόσο του Parkinson. Στην έρευνα πήραν μέρος συνολικά 127 Έλληνες ασθενείς
με την νόσο του Parkinson, που αποτέλεσαν την ομάδα μελέτης και 102 υγιείς, που αποτέλεσαν την ομάδα ελέγχου και οι
οποίοι ελέγχθηκαν ως προς την ύπαρξη του πολυμορφισμού. Από τους 127 ασθενείς με Parkinson που μελετήθηκαν οι 94
ασθενείς έλαβαν ως φαρμακευτική αγωγή L-dopa και από αυτούς οι 24 εμφάνισαν δυσκινησία ως παρενέργεια της φαρ-
μακευτικής αγωγής με L-dopa. Τα αποτελέσματά μας δεν φανερώνουν σημαντική συσχέτιση του rs2298383 πολυμορφισμού
του γονιδίου Adora2A με την νόσο του Parkinson, αλλά ούτε και με την εμφάνιση δυσκινησίας που προκαλείται από την
φαρμακευτική αγωγή με λεβοντόπα σε Έλληνες ασθενείς με νόσο του Parkinson. Αξίζει να σημειωθεί ότι είναι αναγκαίο
να διεξαχθούν ανάλογες έρευνες στον ελληνικό πληθυσμό, όπου οι ομάδες μελέτης θα περιλαμβάνουν μεγαλύτερο αριθμό
ασθενών. Επιπλέον μελέτες και σε άλλους πολυμορφισμούς του γονιδίου Adora2A θα συμβάλλουν σημαντικά τόσο στην
κατανόηση της παθογένεσης της νόσου του Parkinson αλλά και των φαρμακοεπαγώμενων δυσκινησιών.
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Table 1. Genotypes and Alleles’ Frequencies of the rs2298383 polymorphism of Adora2A gene in PD patients and in the
controls in a Greek population.
Genotypes Alleles
Τ/T C/T C/C T C
PD patients
(n=127) 37.8% 47.2% 15% 61.4% 38.6%
Controls 
(n=102) 34.4% 52.9% 12.7% 60.8% 39.2% 
Χ2 P=0.659 P=0.807
Table 2. Genotypes and Alleles’ Frequencies of the rs2298383 polymorphism of Adora2A gene in PD patients with LID
and in PD patients without LID.
Genotypes Alleles
Τ/T C/T C/C T C
PD patients
with LID 42% 42% 16% 62.5% 37.5%
PD patients
without LID 38.5% 44.4% 17.1% 61% 39%
Χ2 P=0.964 P=0.827
